|
|
| Line 1: |
Line 1: |
| == '''What is Herzuma?''' ==
| | #REDIRECT [[Trastuzumab]] |
|
| |
|
| * '''Herzuma''' ([[trastuzumab]]-pkrb) is '''a HER2/neu receptor antagonist''' used for the treatment of [[HER2]]-overexpressing [[breast cancer]], HER2-overexpressing [[metastatic]] gastric or [[gastroesophageal junction adenocarcinoma]].
| | {{redr| |
| | | {{R from trade name}} |
| [[File:Trastuzumab-HER2 complex 1N8Z.png|thumb|Trastuzumab-HER2 complex 1N8Z]]
| | }} |
| | |
| | |
| <youtube>
| |
| title='''{{PAGENAME}}'''
| |
| movie_url=http://www.youtube.com/v/CO0l0ib53GI
| |
| embed_source_url=http://www.youtube.com/v/CO0l0ib53GI
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
| | |
| | |
| == '''What are the uses of this medicine?''' ==
| |
| | |
| Herzuma (trastuzumab-pkrb) is used for the treatment of:
| |
| * HER2-overexpressing [[breast cancer]].
| |
| * HER2-overexpressing [[metastatic]] gastric or [[gastroesophageal junction adenocarcinoma]].
| |
| | |
| | |
| == '''How does this medicine work?''' ==
| |
| | |
| <youtube>
| |
| title='''{{PAGENAME}}'''
| |
| movie_url=http://www.youtube.com/v=jq5cqBeL73M
| |
| embed_source_url=http://www.youtube.com/v=jq5cqBeL73M
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
| | |
| * Trastuzumab (tras tooz’ ue mab) is '''humanized monoclonal antibody to HER2''' which is a human growth factor receptor that is overexpressed in 20% to 25% of breast cancers.
| |
| * The interaction of [[epidermal growth factor]] (EGF) with HER2 results in rapid cell growth and proliferation via intracellular pathways that include MAP and PI3 kinase.
| |
| * '''Binding of trastuzumab to the HER2 receptor blocks this cell signaling pathway and causes growth arrest'''.
| |
| * Trastuzumab was shown to decrease recurrences and prolong survival in women with [[breast cancer]] that were HER2 positive.
| |
| | |
| | |
| == '''Who Should Not Use this medicine ?''' ==
| |
| | |
| * This medicine have no usage limitations.
| |
| | |
| | |
| == '''What drug interactions can this medicine cause?''' ==
| |
| | |
| * Patients who receive [[anthracycline]] after stopping trastuzumab products may be at increased risk of cardiac dysfunction
| |
| * If anthracyclines are used, the patient's cardiac function should be monitored carefully.
| |
| | |
| | |
| == '''Is this medicine FDA approved?''' ==
| |
| | |
| * Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.
| |
| | |
| | |
| == '''How should this medicine be used?''' ==
| |
| | |
| '''Recommended dosage:'''
| |
| | |
| '''Adjuvant Treatment of HER2-Overexpressing Breast Cancer:'''
| |
| * Initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin).
| |
| * One week after the last weekly dose of Herzuma, administer 6 mg/kg as an IV infusion over 30−90 minutes every three weeks to complete a total of 52 weeks of therapy.
| |
| or
| |
| * Initial dose of 8 mg/kg over 90 minute IV infusion, then 6 mg/kg over 30-90 minute IV infusion every three weeks for 52 weeks.
| |
| | |
| '''Metastatic HER2-Overexpressing Breast Cancer:'''
| |
| * Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions.
| |
| | |
| '''Metastatic HER2-Overexpressing Gastric Cancer:'''
| |
| * Initial dose of 8 mg/kg over 90 minute IV infusion, followed by 6 mg/kg over 30 to 90 minute IV infusion every 3 weeks.
| |
| | |
| '''Administration:'''
| |
| * For intravenous (IV) infusion only.
| |
| * Do not administer as an IV push or bolus.
| |
| | |
| | |
| == '''What are the dosage forms and brand names of this medicine?''' ==
| |
| | |
| This medicine is available in fallowing doasage form:
| |
| * '''As Injection:''' 150 mg lyophilized powder in a single-dose vial for [[reconstitution]].
| |
| * '''For Injection:''' 420 mg lyophilized powder in a multiple-dose vial for reconstitution.
| |
| | |
| This medicine is available in fallowing brand namesː
| |
| * '''Herzuma'''
| |
| | |
| | |
| =='''What side effects can this medication cause?'''==
| |
| | |
| The most common side effects of this medicine include:
| |
| | |
| '''In Adjuvant Breast Cancer:'''
| |
| * headache, [[diarrhea]], [[nausea]], and [[chills]]
| |
| | |
| '''In Metastatic Breast Cancer:'''
| |
| * fever, chills, headache, infection, [[congestive heart failure]], [[insomnia]], cough, and rash
| |
| | |
| '''In Metastatic Gastric Cancer:'''
| |
| * [[neutropenia]], diarrhea, fatigue, [[anemia]], [[stomatitis]], weight loss, [[upper respiratory tract infections]], fever, [[thrombocytopenia]], mucosal inflammation, [[nasopharyngitis]], and [[dysgeusia]]
| |
| | |
| | |
| ==''' What special precautions should I follow?''' ==
| |
| | |
| * Administration of trastuzumab products can result in sub-clinical and clinical [[cardiac failure]]. The incidence and severity was highest in patients receiving trastuzumab with [[anthracycline]]-containing chemotherapy regimens. Discontinue Herzuma for cardiomyopathy.
| |
| * Administration of trastuzumab products can result in serious and fatal infusion reactions and [[pulmonary toxicity]]. Discontinue Herzuma for [[anaphylaxis]], [[angioedema]], [[interstitial pneumonitis]], or [[acute respiratory distress syndrome]].
| |
| * Exposure to trastuzumab products during pregnancy can result in [[oligohydramnios]] and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective [[contraception]].
| |
| * Trastuzumab product use can result in serious and fatal pulmonary toxicity. Pulmonary toxicity includes [[dyspnea]], [[interstitial pneumonitis]], [[Pulmonary infiltrate|pulmonary infiltrates]], [[pleural effusions]], non-cardiogenic [[pulmonary edema]], pulmonary insufficiency and [[hypoxia]], [[acute respiratory distress syndrome]], and [[pulmonary fibrosis]].
| |
| | |
| | |
| == '''What to do in case of emergency/overdose?''' ==
| |
| | |
| * {{overdose}}
| |
| | |
| | |
| == '''Can this medicine be used in pregnancy?''' ==
| |
| | |
| * Trastuzumab products can cause fetal harm when administered to a pregnant woman.
| |
| | |
| | |
| =='''Can this medicine be used in children?'''==
| |
| | |
| * The safety and effectiveness of trastuzumab products in pediatric patients have not been established.
| |
| | |
| | |
| == '''What are the active and inactive ingredients in this medicine?''' ==
| |
| | |
| '''Active ingredient:'''
| |
| * TRASTUZUMAB
| |
| | |
| Inactive ingredients:
| |
| * TREHALOSE DIHYDRATE
| |
| * HISTIDINE MONOHYDROCHLORIDE
| |
| * HISTIDINE
| |
| * POLYSORBATE 20
| |
| | |
| | |
| == '''Who manufactures and distributes this medicine?''' ==
| |
| | |
| '''Manufactured by:'''
| |
| * [[Celltrion Inc.|CELLTRION, Inc]].
| |
| * 23, Academy-ro,
| |
| * Yeonsu-gu, Incheon
| |
| * 22014, Republic of Korea
| |
| | |
| * Herzuma® is a registered trademark of CELLTRION, Inc.
| |
| | |
| | |
| == '''What should I know about storage and disposal of this medication?''' ==
| |
| | |
| * Store Herzuma vials in the refrigerator at 2°C to 8°C (36°F to 46°F) until time of [[reconstitution]].
| |
| | |
| | |
| {{coststubd}}
| |
| {{Extracellular chemotherapeutic agents}}
| |
| {{Monoclonals for tumors}}
| |
| {{Growth factor receptor modulators}} | |
| {{portal bar|Medicine}}
| |
| | |
| [[Category:Genentech brands]]
| |
| [[Category:Hoffmann-La Roche brands]]
| |
| [[Category:Immunology]]
| |
| [[Category:Merck & Co. brands]]
| |
| [[Category:Monoclonal antibodies for tumors]]
| |
| [[Category:RTT]]
| |
| [[Category:Specialty drugs]]
| |
| [[Category:World Health Organization essential medicines]]
| |
